Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

use of an effective diuretic dose.

A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

Obeticholic acid was given accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not ...

Atea Pharmaceuticals Inc. (NASDAQ:AVIR) announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, ...

MASH's economic burden is substantial, particularly for patients with MASH and multiple comorbidities, even in the absence of ...

In California, the animal you run over cannot be carted off to your freezer. It must stay by the side of the road. California ...

After hours: September 18 at 5:08 PM EDT Loading Chart for GALT ...

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated price ...

Cirrhotic portal hypertension is characterised by development of the decompensating events of ascites, encephalopathy, portal hypertensive bleeding and hepatorenal syndrome, which arise in a setting ...